EMA Authorised: Ablymico (liraglutide) — STADA Arzneimittel AG

View source ↗

Summary

Ablymico (liraglutide) has been authorised by EMA for obesity and overweight indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Ablymico (liraglutide)

Snippet

Status: Authorised. Therapeutic area: Obesity;Overweight. MAH: STADA Arzneimittel AG. Decision date: 15/07/2026